LFMD
LifeMD, Inc. · Healthcare · Health Information Services
Last
$2.67
−$0.11 (−3.96%) 4:00 PM ET
After hours $2.75 +$0.08 (+3.00%) 5:33 PM ET
Prev close $2.78
Open $2.76
Day high $2.76
Day low $2.65
Volume 591,140
Avg vol 878,171
Mkt cap
$128.52M
P/E ratio
-12.14
FY Revenue
$251.21M
EPS
-0.22
Gross Margin
86.90%
Sector
Healthcare
AI report sections
LFMD
LifeMD, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−29% (Below avg)
Vol/Avg: 0.71×
RSI
39.58 (Weak)
Weak (30–40)
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.00 Signal: 0.00
Short-Term
-0.00 (Weak)
MACD: -0.20 Signal: -0.19
Long-Term
-0.03 (Weak)
MACD: -0.26 Signal: -0.24
Intraday trend score 27.00

Latest news

LFMD 12 articles Positive: 4 Neutral: 2 Negative: 6
Positive Benzinga • Vandana Singh
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost

Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.

NVO CVS COST LFMD weight loss medication Wegovy pill FDA approval pharmaceutical launch
Sentiment note

LifeMD is identified as a telehealth provider offering Wegovy, positioning it to benefit from the growing weight loss medication market demand.

Positive GlobeNewswire Inc. • Na
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD, Inc. announced a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on January 15, 2026. The announcement reflects the company's financial stability as a leading virtual primary care provider.

LFMD LFMDP preferred dividend virtual primary care telemedicine pharmacy services financial performance
Sentiment note

The company is declaring a dividend on preferred stock, which indicates financial stability and profitability. Additionally, the article references strong Q3 2025 results with 13% revenue growth and 20% adjusted EBITDA growth, along with recognition from Deloitte and TIME, all signaling positive business momentum.

Neutral Benzinga • Vandana Singh
Novo Nordisk Leans Into Affordability Amid Rising Competition

Novo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.

NVO LLY COST GDRX obesity weight loss medication pricing healthcare
Sentiment note

Mentioned as a participating telehealth provider

Positive GlobeNewswire Inc. • Lifemd, Inc.
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

LifeMD announced lower cash-pay pricing for Wegovy and Ozempic medications at $199 per month, supporting patients paying out of pocket through its Weight Management Program in collaboration with Novo Nordisk.

LFMD LFMDP NVO LLY GLP-1 weight management virtual healthcare medication pricing
Sentiment note

Expanding affordable medication access, strengthening pharmaceutical partnerships, and positioning itself strategically in the weight management healthcare market

Positive GlobeNewswire Inc. • Towards Healthcare
Non-Sterile Compounding Pharmacy Market Size Expected to Reach USD 12.11 Bn by 2034

The global non-sterile compounding pharmacy market is projected to grow from $5.97 billion in 2024 to $12.11 billion by 2034, driven by increasing demand for personalized medications and growing chronic diseases, with North America currently leading the market.

LFMD LFMDP compounding pharmacy personalized medicine healthcare market pharmaceutical innovation
Sentiment note

Announced expansion of non-sterile compounding capabilities in September 2025

Negative Benzinga • Prnewswire
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against LifeMD for allegedly making false and misleading statements about its competitive position and financial guidance during May-August 2025.

LFMD LFMDP securities fraud lawsuit class action investor rights
Sentiment note

The company is accused of misleading investors by raising fiscal year 2025 performance guidance without proper basis, and making false statements about its competitive position, which potentially caused investor damages

Neutral GlobeNewswire Inc. • Rosen Law Firm
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims for Telix Pharmaceuticals shareholders after the company received an SEC subpoena related to prostate cancer therapeutic candidate disclosures, which caused a 10.44% stock price drop.

TLX LFMD LFMDP securities claim subpoena SEC prostate cancer investor losses
Sentiment note

Mentioned briefly in secondary article with no specific negative or positive details provided

Negative GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc
LFMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that LifeMD, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against LifeMD, alleging false statements about the company's competitive position and financial guidance for 2025, with potential securities law violations.

LFMD LFMDP class action securities lawsuit investor alert financial disclosure
Sentiment note

Lawsuit alleges material misstatements about company's competitive position, financial guidance, and customer acquisition costs, suggesting potential financial misconduct and investor harm

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
LIFEMD CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges LifeMD Investors to Contact the Firm Before October 27th Regarding Filed Class Action

A class action lawsuit has been filed against LifeMD alleging false statements about the company's competitive position and financial guidance during May 7-August 5, 2025, with investors having until October 27th to apply as lead plaintiff.

LFMD LFMDP class action securities lawsuit investor rights
Sentiment note

The lawsuit alleges the company made materially false and misleading statements about its competitive position, financial guidance, and customer acquisition costs, suggesting significant potential financial and reputational damage

Negative GlobeNewswire Inc. • Rosen Law Firm
מחר המועד אחרון לתביעה נגד LFMD: רוזן, משרדי עורכי דין מכובד ברחבי העולם, מעודד את משקיעי LifeMD, Inc. להשיג ייעוץ לפני המועד האחרון החשוב של 27 באוקטובר בתביעה ייצוגית בניירות ערך שהוגשה ראשונה על ידי המשרד – LFMD

Rosen Law Firm reminds LifeMD investors of an important October 27, 2025 deadline for a securities class action lawsuit, alleging the company made false or misleading statements about its competitive position and financial guidance.

LFMD LFMDP securities lawsuit investor rights class action financial disclosure
Sentiment note

The lawsuit alleges the company made materially false statements about its competitive position, financial guidance, and customer acquisition costs, suggesting potential financial misrepresentation and investor harm

Negative GlobeNewswire Inc. • Rosen Law Firm
LFMD DEADLINE TOMORROW: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages LifeMD, Inc. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class Action First Filed by the Firm – LFMD

Rosen Law Firm reminds LifeMD investors of an important October 27, 2025 deadline for a securities class action lawsuit, alleging the company made false or misleading statements about its competitive position and financial guidance.

LFMD LFMDP securities class action investor rights lawsuit financial disclosure
Sentiment note

The lawsuit alleges the company made materially false statements about its competitive position, raised unrealistic 2025 guidance without properly accounting for customer acquisition costs, and potentially misled investors about its business prospects

Negative GlobeNewswire Inc. • Hagens Berman
LFMD 2-DAY DEADLINE ALERT: Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements -- Hagens Berman

A federal securities fraud lawsuit has been filed against LifeMD, alleging the telehealth company misled investors about its financial health and growth prospects during May-August 2025, resulting in a significant stock price decline.

LFMD LFMDP securities fraud telehealth investor lawsuit stock price earnings report
Sentiment note

The company is accused of making false and misleading statements about its financial performance, customer acquisition costs, and business challenges, which led to a 44% stock price drop after revealing operational issues in its Q2 earnings report

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal